Her clinical practice primarily focuses on interstitial lung disease (ILD) and she is the Director of the ILD Clinic. ILD is a disease category that encompasses many pulmonary conditions, including idiopathic pulmonary fibrosis (IPF), autoimmune lung diseases, and sarcoidosis. Dr. Scholand is the principal investigator on numerous clinical trials which aim to find a treatment for pulmonary fibrosis (both idiopathic and autoimmune in etiology), and is a co-investigator in NIH-funded studies on IPF and chronic obstructive pulmonary disease. In addition, Dr. Scholand studies the relationship between genetic and phenotypic variation to identify genes that significantly elevate the risk of developing ILD, and thus to find new therapeutic targets.